PACE Funds £6M to Fight Resistant Bacteria

Summary of the Article: PACE Funding too Combat Antimicrobial Resistance

This ⁤article details the launch of the third funding round by Pathways to ⁤Antimicrobial Clinical efficacy (PACE), a UK ⁢initiative aimed at addressing the growing crisis of antimicrobial resistance (AMR). Here’s a breakdown of the key points:

* The Problem: Antibacterial drugs are becoming less effective due to existing resistance mechanisms.If unchecked, AMR could lead to over 8 million deaths annually by 2050 adn cost the global economy $100 trillion.
* The Solution: PACE Initiative: PACE is a £30m public-private collaboration (backed by Innovate UK,⁢ LifeArc, and Medicines Revelation Catapult) designed to bolster antimicrobial research.
* Third Funding Round: The latest round offers up to £6 million to⁣ support up to eight projects focused on tackling bacterial infections with the⁤ highest AMR burden. Prosperous applicants can receive up to £1 million over two⁢ years.
* Focus Areas: PACE is prioritizing⁤ research into life-threatening infections like lower respiratory tract infections, urinary tract infections, ⁢and bloodstream infections,‍ which are increasingly arduous to treat and can lead to sepsis.
* Expert Opinion: Professor Dame Sally Davies emphasizes the urgency of the situation, stating that without new antibiotics and ⁤diagnostics, modern medicine will be compromised, economies will⁤ suffer, and lives will be lost. She highlights PACE as a crucial investment in safeguarding future health.

In essence, the article highlights a notable investment in research and development to combat the escalating threat of antibiotic resistance and protect global health.